Arch Biopartners Announces Listing on OTCQB Exchan

TORONTO, May 16, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, announced that the Company’s common shares have been approved to begin trading today on the OTCQB Venture Market (OTCQB) under the ticker ACHFF.

“Listing on the OTCQB will help our company engage a larger network of U.S. investors and media partners. It also provides U.S. investors with improved market access to trade our shares and access our public filings, similar to what is available to investors in our home exchange,” said Richard Muruve, CEO of Arch.

The OTCQB is recognized by the U.S. Securities Exchange Commission (SEC) as an established public market. Eligible companies do not have Sarbanes-Oxley and SEC Reporting requirements to trade on OTCQB, bypassing costly and duplicative NYSE and NASDAQ listing requirements. The OTCQB market is primarily for early-stage and developing companies. To be eligible, international companies must be listed on a qualified foreign stock exchange, be current in their regulatory filings and complete an annual verification and management certification.

The Company’s common shares will continue to trade on the TSX Venture Exchange under the symbol ARCH.

About Arch Biopartners

Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact.  Arch has established a diverse portfolio that includes Metablok (LSALT peptide), a potential treatment for inflammation, sepsis and cancer metastasis; AB569, a potential new treatment for antibiotic resistant bacterial infections in the lung, urinary tract or wounds; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.

For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com

The Company has 57,799,679 common shares outstanding.

For more information, please contact:

Richard Muruve Chief Executive Officer Arch Biopartners, Inc. 647-428-7031 info@archbiopartners.com  

Forward-Looking Statements

All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.